Shire Finds Big Value in Rare Diseases, and a Strong Growth Path for its Boston Unit

Shire’s CEO discusses the company’s upcoming move into gene therapy and stem cell research, two promising areas of development that have yet to yield effective therapies. Shire’s Boston-based unit is leading the company‚Äôs efforts in rare and orphan diseases, a move that many companies have followed.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail